Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

RU 486. The progesterone antagonist

¹Department of Family and Community Medicine, University of Arizona College of Medicine, Tucson.

Archives of Family Medicine

|January 1, 1993

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Health literacy: an important issue for communicating health information to patients.

Zhonghua yi xue za zhi = Chinese medical journal; Free China ed·2002

Same author

Longitudinal residency training in family medicine: not ready for prime time.

Family medicine·2001

Same author

POEMS (patient-oriented evidence that matters) spark discussion.

The Journal of family practice·2001

Same author

Management of MVP with antibiotic prophylaxis.

American family physician·2001

Same author

Critical requirement for the membrane-proximal cytosolic tyrosine residue for CD28-mediated costimulation in vivo.

Journal of immunology (Baltimore, Md. : 1950)·2001

Same author

Novel role of phosphatidylinositol 3-kinase in CD28-mediated costimulation.

The Journal of biological chemistry·2000

Same journal

Living in medicine: med school after 50 years plus 2 weeks

Archives of family medicine·2000

Same journal

Phytophotodermatitis: a sometimes difficult diagnosis.

Archives of family medicine·2000

Same journal

Case description of ascariasis.

Archives of family medicine·2000

Same journal

Microscopic polyangiitis in a pediatric patient.

Archives of family medicine·2000

Same journal

Advance care planning.

Archives of family medicine·2000

Same journal

Gaps in end-of-life care.

Archives of family medicine·2000

See all related articles

Mifepristone (RU 486) is a progesterone antagonist effective for first-trimester abortions and Cushing's syndrome treatment. It shows promise for treating cancers and endocrine conditions like endometriosis.

Area of Science:

Pharmacology
Endocrinology
Oncology

Background:

RU 486 (mifepristone) is a significant drug with dual antagonist properties.
Its therapeutic applications span reproductive health, endocrine disorders, and oncology.

Purpose of the Study:

To review the current and potential therapeutic uses of mifepristone (RU 486).
To consolidate findings on its mechanism of action, clinical indications, and future applications.

Main Methods:

Literature review of peer-reviewed publications from 1987-1992 via Index Medicus.
Inclusion of human, animal, and tissue culture experimental data.

Main Results:

Mifepristone is effective for first-trimester abortions, cervical ripening, and postcoital contraception.

Related Experiment Videos

It serves as a glucocorticoid antagonist for Cushing's syndrome.

Investigational uses include antineoplastic therapy for meningioma, breast cancer, prostate cancer, and hepatoma, as well as endometriosis and PMS.

Conclusions:

Mifepristone is clinically established for reproductive indications and Cushing's syndrome.
It holds significant therapeutic potential for various neoplasms and endocrinologic conditions.